Cargando…

Trévo abrogates Lead Acetate Neurotoxicity in Male Wistar Rats viz Antiamyloidogenesis, Antiglutaminergic, and Anticholinesterase Activities

BACKGROUND: Exposure to lead has been linked to biochemical changes similar to those patients suffering from Alzheimer’s disease. Trévo is a phytonutrient-rich product with antiaging and antioxidant properties. PURPOSE: To investigate the neuroprotective activity of trévo against lead-induced bioche...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilesanmi, Omotayo B., Odewale, Temitope Temiloluwa, Avwioroko, Oghenetega J., Ahmed, Eman Ibrahim, Alaneme, Chinenyenwa, Atanu, Francis O., Chikere, Bruno, James, Millicent, Chinagor, Innocent, Albezrah, Nisreen Khalid Aref, Youssef, Amal, Binang, Toyin, Batiha, Gaber El-Saber
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9676341/
https://www.ncbi.nlm.nih.gov/pubmed/36419514
http://dx.doi.org/10.1177/09727531221077642
Descripción
Sumario:BACKGROUND: Exposure to lead has been linked to biochemical changes similar to those patients suffering from Alzheimer’s disease. Trévo is a phytonutrient-rich product with antiaging and antioxidant properties. PURPOSE: To investigate the neuroprotective activity of trévo against lead-induced biochemical changes in male Wistar rats. METHODS: The study involves 35 animals that were randomly divided into five groups of seven rats each. Group I (Control): Orally administered distilled water; Group II (Induced): Administered 15 mg/kg of lead acetate (PbA) intraperitoneally; Group III (Treatment group): Orally administered 2 mL/kg of trévo for two days before co-administration with PbA for 12 consecutive days; Group IV (Treatment group): Orally administered 5 mL/kg of trévo for two days prior to coadministration with PbA for 12 consecutive days; Group V: Orally administered 5 mL/kg of trévo for 14 consecutive days. Animals were anesthetized with diether and the brain excised and processed for the following biochemical assays: Malonedialdehyde (MDA), glutathione (GSH), catalase (CAT), superoxide dismutase (SOD), glutathione-S-transferase (GT), acetylcholinesterase (AChE), beta-amyloid, glutamate, Na+/K+ ATPase, and glutamate dehydrogenase (GD). RESULTS: PbA caused significant oxidative stress (increased MDA concentration, decreased GSH concentration, suppressed the activity of CAT, SOD), decreased GT activity, increased activity of AChE, increased the concentration of beta-amyloid, and caused glutamate excitotoxicity (increased concentration of glutamate, decreased activity of Na+/K+ ATPase, and GD) in rat brains. Treatment with trévo at the two different doses significantly prevented oxidative damage, beta-amyloid aggregation, glutamate excitotoxicity, and acetylcholine breakdown induced by lead acetate. CONCLUSION: Our findings added to the reported pharmacological activity of trévo and supported the antiaging potential of trévo.